NASDAQ:SGMO

Sangamo Therapeutics (SGMO) Stock Forecast, Price & News

$0.63

-0.05 (-7.43%)

(As of 02:26 PM ET)

Compare

Today's Range: $0.60
▼
$0.72
50-Day Range: $0.68
▼
$1.47
52-Week Range: $0.60
▼
$5.27

Volume: 1.14 million shs
Average Volume: 1.94 million shs
Market Capitalization: $110.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.80

Sangamo Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 772.3% Upside
$5.80 Price Target
Short Interest: Healthy
5.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.84) to ($0.97) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

608th out of 963 stocks

Biological Products, Except Diagnostic Industry

97th out of 159 stocks

4.4

Analyst's Opinion

Consensus Rating
Sangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $5.80, Sangamo Therapeutics has a forecasted upside of 772.3% from its current price of $0.66.
Amount of Analyst Coverage
Sangamo Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
5.43% of the outstanding shares of Sangamo Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Sangamo Therapeutics has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Sangamo Therapeutics has recently decreased by 8.13%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sangamo Therapeutics does not currently pay a dividend.
Dividend Growth
Sangamo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SGMO.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Sangamo Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 6 people have searched for SGMO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
9 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Sangamo Therapeutics is held by insiders.
Percentage Held by Institutions
59.81% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sangamo Therapeutics are expected to decrease in the coming year, from ($0.84) to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sangamo Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sangamo Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sangamo Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

SGMO Price History

30 days | 90 days | 365 days | Advanced Chart

SGMO Stock News Headlines

September 22, 2023 | americanbankingnews.com

StockNews.com Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to "Sell"

September 8, 2023 | msn.com

Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 4, 2023 | finance.yahoo.com

Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past year

September 2, 2023 | finance.yahoo.com

Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases

August 15, 2023 | markets.businessinsider.com

Analyst Ratings for Sangamo Therapeutics

August 15, 2023 | nasdaq.com

HC Wainwright & Co. Reiterates Sangamo Therapeutics (SGMO) Buy Recommendation

August 15, 2023 | finance.yahoo.com

Time To Worry? Analysts Are Downgrading Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 15, 2023 | finance.yahoo.com

Does This Valuation Of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Imply Investors Are Overpaying?

August 14, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

August 11, 2023 | msn.com

Wedbush Maintains Sangamo Therapeutics (SGMO) Outperform Recommendation

August 11, 2023 | msn.com

Wells Fargo Maintains Sangamo Therapeutics (SGMO) Overweight Recommendation

August 8, 2023 | finance.yahoo.com

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

August 8, 2023 | finance.yahoo.com

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

August 8, 2023 | benzinga.com

A Preview Of Sangamo Therapeutics's Earnings

August 1, 2023 | finance.yahoo.com

Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast

July 21, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG)

July 20, 2023 | finance.yahoo.com

Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing

July 19, 2023 | finance.yahoo.com

The past five years for Sangamo Therapeutics (NASDAQ:SGMO) investors has not been profitable

July 18, 2023 | marketwatch.com

Sangamo Therapeutics Signs Virus Capsid Research Evaluation and Option Agreement With Eli Lilly's Prevail

July 17, 2023 | markets.businessinsider.com

Sangamo Inks Evaluation And Option Agreement With Lilly's Prevail For Adeno-associated Virus Capsids

July 17, 2023 | finance.yahoo.com

Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids

June 29, 2023 | markets.businessinsider.com

Sangamo Gets License To Combine Voyager TRACER Capsid With Sangamo's ZF-TRs To Treat Prion Disease

June 29, 2023 | finance.yahoo.com

Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease

June 15, 2023 | insidermonkey.com

5 DNA Stocks Billionaires Are Loading Up On

June 14, 2023 | finance.yahoo.com

We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

See More Headlines

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Company Calendar

Last Earnings: 8/08/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:SGMO
CUSIP: 80067710
CIK: 1001233
Web: www.sangamo.com
Phone: (510) 970-6000
Fax: 510-236-8951
Employees: 478
Year Founded: 1995

Price Target and Rating

Average Stock Price Forecast: $5.80
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +852.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-192,280,000.00
Net Margins: -90.86%
Pretax Margin: -93.50%
Return on Equity: -50.17%
Return on Assets: -30.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.97
Quick Ratio: 2.97

Sales & Book Value

Annual Sales: $111.30 million
Price / Sales: 0.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.80 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 177,110,000
Free Float: 171,799,000
Market Cap: $107.82 million
Optionable: Optionable
Beta: 1.10

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Alexander D. Macrae Ch.B (Age 60)
M.B., MRCP, Ph.D., CEO, Pres & Director
Comp: $1.17M

Ms. Prathyusha Duraibabu CPA (Age 44)
M.B.A., Sr. VP, CFO & Principal Accounting Officer
Comp: $628.08k

Mr. D. Mark McClung (Age 60)
Exec. VP & COO
Comp: $710.3k

Dr. Jason D. Fontenot Ph.D. (Age 53)
Sr. VP & Chief Scientific Officer
Comp: $682.76k

Phillip Ramsey
Head of Technical Operations

Ms. Aron Feingold
Head of Corp. Communications & Investor Relations Officer

Mr. Scott B. Willoughby (Age 48)
Sr. VP, Gen. Counsel & Corp. Sec.

Ms. Whitney Jones
Chief People Officer

Dr. Nathalie Dubois-Stringfellow Ph.D. (Age 61)
Sr. VP & Chief Devel. Officer

Dr. Lisa Rojkjaer M.D. (Age 57)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SGMO Stock - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SGMO shares.
View SGMO analyst ratings or view top-rated stocks.
What is Sangamo Therapeutics' stock price forecast for 2023?: 7 equities research analysts have issued 1-year price targets for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $1.50 to $10.00. On average, they anticipate the company's share price to reach $5.80 in the next year. This suggests a possible upside of 852.7% from the stock's current price.
View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts.
How have SGMO shares performed in 2023?: Sangamo Therapeutics' stock was trading at $3.14 at the beginning of 2023. Since then, SGMO stock has decreased by 80.6% and is now trading at $0.6088.
View the best growth stocks for 2023 here.
When is Sangamo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our SGMO earnings forecast.
How were Sangamo Therapeutics' earnings last quarter?: Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. The biopharmaceutical company earned $6.84 million during the quarter, compared to the consensus estimate of $22.33 million. Sangamo Therapeutics had a negative net margin of 90.86% and a negative trailing twelve-month return on equity of 50.17%.
What ETFs hold Sangamo Therapeutics' stock?: ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM).
What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?: 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).
What is Sangamo Therapeutics' stock symbol?: Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."
Who are Sangamo Therapeutics' major shareholders?: Sangamo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Wasatch Advisors LP (9.92%), BlackRock Inc. (8.97%), Credit Suisse AG (2.09%), Renaissance Technologies LLC (1.73%), Geode Capital Management LLC (1.61%) and Acadian Asset Management LLC (1.64%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry.
View institutional ownership trends.
How do I buy shares of Sangamo Therapeutics?: Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sangamo Therapeutics' stock price today?: One share of SGMO stock can currently be purchased for approximately $0.61.
How much money does Sangamo Therapeutics make?: Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $107.82 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.
How many employees does Sangamo Therapeutics have?: The company employs 478 workers across the globe.
How can I contact Sangamo Therapeutics?: Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.

This page (NASDAQ:SGMO) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial